Quick Listen: Scrip’s Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: an interview with the president of Novartis Pharma; Biogen highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 24 September 2021, including: an interview with the president of Novartis AG Pharma; Biogen, Inc. highlights its pipeline; standout comparative data for Enhertu in breast cancer; Sanofi/Regeneron Pharmaceuticals, Inc. nip at Keytruda’s heels in first-line lung cancer; and a look at the market prospects for wet AMD.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Looking Past Aduhelm, Biogen Puts Pipeline On Display" - Scrip, 22 Sep, 2021.)
(Also see "Enhertu Poised To Rewrite The Standard Of Care After ESMO" - Scrip, 20 Sep, 2021.)
(Also see "ESMO: Regeneron Mounts Credible Challenge To Keytruda With Libtayo Survival Data In NSCLC" - Scrip, 20 Sep, 2021.)
(Also see "Wet AMD Market Snapshot: A High-Growth Market Poised For Change" - Scrip, 17 Sep, 2021.)